Evogene Ltd (EVGN) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Evogene Ltd (EVGN) advanced +1.60% to $0.38, trading at 3% of its 52-week range ($0.35 – $1.28). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules for the pharmaceutical and agricultural industries, today announced ac
Advancing a First-in-Class Small-Molecule Therapeutic, Guided by World-Leading Experts, to Address a Multi-Billion-Dollar Unmet Need in Steroid-Refractory PatientsREHOVOT, Israel, Oct. 28, 2026 /PRNewswire/ -- Evogene
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced it
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules for pharmaceutical and agricultural applications, today announced its
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on EVGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for EVGN. Explore sector supply chains on /butterfly.
Across 270 tracked Materials securities in the Roarable RQD universe, Evogene Ltd (EVGN) ranks #70 by composite RQD confidence (59/100, grade C-) and #264 by equity capitalization ($6.0M). Within this direct 5-issuer industry benchmark cohort, EVGN leads on earnings valuation at N/A trailing P/E, while AVD leads on capital efficiency and profitability with -6.1% ROIC and 28.6% gross margin. EVGN currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EVGN
ACTIVE
Evogene Ltd | C- | 59/100 | — | — | — | +1.60% | $6.0M | Benchmark Subject |
| SNES SenesTech Inc. | D | 45/100 | — | 62.5% | -35.0% | +4.12% | $5.5M | /snes-vs-evgn → |
| FRTT Fort Technology Inc. | D+ | 56/100 | — | — | — | -3.14% | $8.1M | /frtt-vs-evgn → |
| NXTS Nexentis Technologies Inc. | D- | 42/100 | — | — | -27.4% | +0.40% | $1.9M | /nxts-vs-evgn → |
| AVD American Vanguard Corporation ($0.10 Par Value) | D- | 35/100 | — | 28.6% | -6.1% | -3.51% | $32.5M | /avd-vs-evgn → |
Evogene Ltd (EVGN) operates in Agricultural Chemicals (Materials) with an equity capitalization of $6.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Evogene Ltd (NASDAQ: EVGN) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $0.38 (+1.60% 1D, market cap $6.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 270 tracked Materials issuers, EVGN ranks #70 in composite RQD confidence.
Within the Materials sector (Agricultural Chemicals), EVGN carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SNES (SenesTech Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and FRTT (Fort Technology Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $8.1M). Among the 5-stock peer group, EVGN leads on earnings multiple (N/A) while AVD leads on capital efficiency (-6.1% ROIC).
For Evogene Ltd (EVGN), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side. and sector rank #70 in Materials, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
EVGN last traded at $0.38 (+1.60% on volume of 13,847 shares), positioning the stock -15.56% below its 50-day simple moving average ($0.45) and -42.42% below its 200-day simple moving average ($0.66). Across its 52-week range of $0.35 to $1.28, EVGN sits at the 3.2% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.43).
Why EVGN Stock advanced +1.60% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.